Literature DB >> 25690486

The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors.

Akira Yoshioka1, Eizaburo Ishii, Tamaki Ueno, Ikuya Usami, Masao Kobayashi, Ryoji Kobayashi, Manabu Sotomatsu, Akira Shirahata, Takashi Suzuki, Masashi Taki, Yasushi Ishida, Tadashi Matsushita, Midori Shima, Keiji Nogami, Michio Sakai, Hisato Kigasawa, Katsuyuki Fukutake.   

Abstract

The International Immune Tolerance Induction (I-ITI) Study in hemophilia A patients with inhibitors included 16 Japanese patients among a total of 115 test subjects. The results within this group of Japanese patients were 11 cases of I-ITI off-study, three cases of I-ITI on-study, and two cases of tolerance on prophylaxis. There was no significant difference in success rate between the low-dose and high-dose groups (Study I). Successively, independent follow-up survey in Japan was conducted in 14 cases, with consent (Study II). Ten cases were off-study at the end of the I-ITI Study. Of these 10 cases, seven of seven successful cases remained clinical successes at the end of the follow-up study, one partial success became a full success while a second relapsed, and one failure was subsequently evaluated as a partial success. Four cases that were on-study at the end of I-ITI Study were classified as three successes and one failure at the end of the follow-up study. As a result, the status at the end of follow-up study was: 11 ITI successes (78.6 %); one partial success; one failure; and one relapse. Thus, the ITI follow-up study was helpful in providing a long-term prognostic determination of inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25690486     DOI: 10.1007/s12185-015-1734-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

1.  The principal results of the International Immune Tolerance Study: a randomized dose comparison.

Authors:  Charles R M Hay; Donna M DiMichele
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

2.  The international immune tolerance study: a multicenter prospective randomized trial in progress.

Authors:  D M Dimichele; C R M Hay
Journal:  J Thromb Haemost       Date:  2006-07-17       Impact factor: 5.824

3.  Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Authors:  J Astermark; M Morado; A Rocino; H M van den Berg; M von Depka; A Gringeri; L Mantovani; R P Garrido; M Schiavoni; A Villar; J Windyga
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

4.  The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.

Authors:  D DiMichele; B Kroner
Journal:  Haematologica       Date:  2000-10       Impact factor: 9.941

  4 in total
  2 in total

1.  Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.

Authors:  Yoko Mizoguchi; Aya Furue; Reiko Kagawa; Ikue Chijimatsu; Keita Tomioka; Maiko Shimomura; Yusuke Imanaka; Shiho Nishimura; Satoshi Saito; Mizuka Miki; Atsushi Ono; Nakao Konishi; Hiroshi Kawaguchi; Masao Kobayashi
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

2.  Final Results of the Prospective ADVATE® Immune Tolerance Induction Registry (PAIR) Study with Plasma- and Albumin-Free Recombinant Factor VIII.

Authors:  Amy D Shapiro; Alejandro Fernandez; Jerome Teitel; Jaco Botha; Kate Khair
Journal:  J Blood Med       Date:  2021-11-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.